



ESMO CONGRESS STOCKHOLM 2008 PROGRAM

Keynote lectures

Saturday, 13 September 2008, 12:45-13:35, Victoria Hall

| Topic | Basic science |
|---------|---------------------|
| Chair | Martine Piccart, BE |
| Speaker | René Bernards, BE |

Sunday, 14 September 2008, 12:30-13:20, Victoria Hall

| Topic | Breast cancer |
|---------|------------------|
| Chair | José Baselga, ES |
| Speaker | Larry Norton, US |

Monday, 15 September 2008, 12:30-13:20, Victoria Hall

| Topic | Renal cancer |
|---------|-----------------------|
| Chair | Carsten Bokemeyer, DE |
| Speaker | William Kaelin, US |





<u>Special Symposium</u> – ESMO/ESTRO/ESSO

Saturday, 13 September 2008, 11:00-12:30, Auditorium A6

| - Cutaruay, 10 Coptoni | DEI 2000, 11.00-12.00, Auditorium A0 |
|------------------------|---|
| Title symposium | ESMO/ESTRO/ESSO Joint Symposium: Integration of targeted therapies with radiation |
| Co-Chair | Vincent Gregoire, BE |
| Co-Chair | Rolf A. Stahel, CH |
| Title presentation 1 | Introduction |
| Speaker 1 | Vincent Gregoire, BE |
| Lecture time 1 | 5' |
| Title presentation 2 | Where we are with radiation modifiers? A pre-clinical overview |
| Speaker 2 | Michael Baumann, DE |
| Lecture/disc time 2 | 20' |
| Title presentation 3 | Head and neck cancer |
| Speaker 3 | James Bonner, US |
| Lecture/disc time 3 | 20' |
| Title presentation 4 | Lung cancer |
| Speaker 4 | Robert Pirker, AT |
| Lecture/disc time 4 | 20' |
| Title presentation 5 | Surgical issues in rectal cancer |
| Speaker 5 | Irving Taylor, GB |
| Lecture/disc time 5 | 20' |
| Title presentation 6 | Conclusions |
| Speaker 6 | Rolf A. Stahel, CH |
| Lecture/disc time 6 | 5' |





Special Symposium - Chest tumors

Sunday, 14 September 2008, 11:00-12:30, Auditorium A3/4

| Sunday, 14 September | 1 2006, 11:00-12:50, Auditorium A3/4 |
|----------------------|---|
| Title symposium | Innovative approaches to NSCLC |
| Chair | Wilfried Eberhardt, DE |
| Co-Chair | Egbert Smit, NL |
| Title presentation 1 | Introduction |
| Speaker 1 | Wilfried Eberhardt, DE |
| Lecture time 1 | 5' |
| Title presentation 2 | The impact of imaging techniques on choice of treatment |
| Speaker 2 | Harry Groen, NL |
| Lecture/disc time 2 | 20' |
| Title presentation 3 | Novel approaches for stage I lung cancer |
| Speaker 3 | Suresh Senan, NL |
| Lecture/disc time 3 | 20' |
| Title presentation 4 | Pre-or postoperative chemotherapy for stage II lung cancer? |
| Speaker 4 | Marianne Nicolson, GB |
| Lecture/disc time 4 | 20' |
| Title presentation 5 | Tailoring therapy: Dream or reality? |
| Speaker 5 | Jean-Charles Soria, FR |
| Lecture/disc time 5 | 20' |
| Title presentation 6 | Conclusions |
| Speaker 6 | Egbert F. Smit, NL |
| Lecture/disc time 6 | 5' |





<u>Special Symposium</u> - Gynecological cancers

Sunday, 14 September 2008, 11:00-12:30, Auditorium A6

| , | Toward the varies in a varies and and matrial conserve |
|----------------------|---|
| Title symposium | Targeted therapies in ovarian and endometrial cancers |
| Chair | Jonathan Ledermann, GB |
| Co-Chair | Cristiana Sessa, CH |
| Title presentation 1 | Introduction |
| Speaker 1 | Jonathan Ledermann, GB |
| Lecture time 1 | 5' |
| Title presentation 2 | The double standard of hitting the cell |
| Speaker 2 | Cristiana Sessa, CH |
| Lecture/disc time 2 | 20' |
| Title presentation 3 | PARP |
| Speaker 3 | Hilary Calvert, GB |
| Lecture/disc time 3 | 20' |
| Title presentation 4 | mTOR |
| Speaker 4 | Amit Oza, CA |
| Lecture/disc time 4 | 20' |
| Title presentation 5 | The role of targeted drugs in combination with standard chemotherapy in the treatment of ovarian cancer |
| Speaker 5 | Michael Bookman, US |
| Lecture/disc time 5 | 20' |
| Title presentation 6 | Conclusions |
| Speaker 6 | Christiana Sessa, CH |
| Lecture/disc time 6 | 5' |





Special Symposium - Genitourinary tumors

Sunday, 14 September 2008, 13:45-15:15, Auditorium A3/4

| Gunday, 14 Ocptembe | |
|----------------------|---|
| Title symposium | Renal cell cancer: A look to the future |
| Chair | Cora Sternberg, IT |
| Co-Chair | Ian Tannock, CA |
| Title presentation 1 | Introduction |
| Speaker 1 | Cora Sternberg, IT |
| Lecture time 1 | 5' |
| Title presentation 2 | VEGF biology and resistance |
| Speaker 2 | Jim Brugarolas, US |
| Lecture/disc time 2 | 20' |
| Title presentation 3 | mTOR |
| Speaker 3 | Gary Hudes, US |
| Lecture/disc time 3 | 20' |
| Title presentation 4 | Ongoing international clinical trials |
| Speaker 4 | Bernard Escudier, FR |
| Lecture/disc time 4 | 20' |
| Title presentation 5 | What are the problems to be solved in the future? |
| Speaker 5 | Martin Gore, GB |
| Lecture/disc time 5 | 20' |
| Title presentation 6 | Conclusions |
| Speaker 6 | Ian Tannock, CA |
| Lecture/disc time 6 | 5' |





<u>Special Symposium</u> - ESMO Developing Countries Task Force / UICC / WHO

Sunday, 14 September 2008, 14:45-16:15, Auditorium A1

| | 2006, 14:45-16:15, Additional AT |
|----------------------|---|
| Title Symposium: | The cancer burden in developing countries: The role of prevention |
| Chair | Franco Cavalli, CH |
| Co-Chair | Eduardo Cazap, AR |
| Title presentation 1 | Introduction |
| Speaker 1 | Eduardo Cazap, AR |
| Lecture time 1 | 5' |
| Title presentation 2 | Prevention in lung cancer: A vision from India |
| Speaker 2 | Purvish Parikh, IN |
| Lecture time 2 | 20' |
| Title presentation 3 | Prevention in breast cancer: Epidemiology and prevention in Arab countries |
| Speaker 3 | Nagi El Saghir, LB |
| Lecture/disc time 3 | 20' |
| Title presentation 4 | Primary prevention in cervical cancer (including a vision from Latin America) |
| Speaker 4 | Eduardo Cazap, AR |
| Lecture/disc time 4 | 20' |
| Title presentation 5 | The role of government in cancer prevention |
| Speaker 5 | Adamos Adamou, CY |
| Lecture/disc time 5 | 10' |
| Title presentation 6 | GAPAC: the global initiative of WHO against cancer |
| Speaker 6 | Andreas Ullrich, CH |
| Lecture/disc time 6 | 10' |
| Title presentation 7 | Conclusions |
| Speaker 7 | Franco Cavalli, CH |
| Lecture/disc time 7 | 5' |





Special Symposium - Head and neck cancer

Sunday, 14 September 2008, 15:30-17:00, Auditorium A6

| ounday, 14 ocptomber | 2006, 15:50-17:00, Additorium A0 |
|----------------------|---|
| Title symposium | Head and neck cancer |
| Chair | Jean Bourhis, FR |
| Co-Chair | Jan Vermorken, BE |
| Title presentation 1 | Introduction |
| Speaker 1 | Jan Vermorken, BE |
| Lecture time 1 | 5' |
| Title presentation 2 | Innovative radiotherapy in head and neck cancer: IMRT and image guided RT |
| Speaker 2 | Chris Nutting, GB |
| Lecture/disc time 2 | 20' |
| Title presentation 3 | The optimal use of chemotherapy in a multi-disciplinary approach |
| Speaker 3 | Marco Merlano, IT |
| Lecture/disc time 3 | 20' |
| Title presentation 4 | How to integrate EGFR targeting in the management of head and neck cancer |
| Speaker 4 | Jan Vermorken, BE |
| Lecture/disc time 4 | 20' |
| Title presentation 5 | Beyond EGFR targeting |
| Speaker 5 | Kevin Harrington, GB |
| Lecture/disc time 5 | 20' |
| Title presentation 6 | Conclusions |
| Speaker 6 | Jean Bourhis, FR |
| Lecture/disc time 6 | 5' |





<u>Special symposium</u> - Basic science and translational research

Monday, 15 September 2008, 09:00-10:30, Victoria Hall

| , | 2000, 05:00-10:00, Victoria rian |
|----------------------|---|
| Title symposium | Large scale molecular analyses for target discovery: From the bedside to the bench |
| Chair | Christoph A. Klein, DE |
| Co-Chair | René Bernards, NL |
| Title presentation 1 | Introduction |
| Speaker 1 | René Bernards, NL |
| Lecture time 1 | 5' |
| Title presentation 2 | Gene expression profile for target discovery |
| Speaker 2 | Lajos Pusztai, US |
| Lecture/disc time 2 | 17' |
| Title presentation 3 | MicroRNA in cancer: Will they enable the identification of new targets? |
| Speaker 3 | Christos Sotiriou, BE |
| Lecture/disc time 3 | 17' |
| Title presentation 4 | SiRNA libraries: Identification of the 'Achille's heel' |
| Speaker 4 | René Bernards, NL |
| Lecture/disc time 4 | 17' |
| Title presentation 5 | Identification of disease-specific molecular abnormalities by reverse phase Protein array |
| Speaker 5 | Gordon Mills, US |
| Lecture/disc time 5 | 17' |
| Title presentation 5 | Conclusion: Will large scale screening lead to the identification of therapeutic targets? |
| Speaker 5 | Christoph A. Klein, DE |
| Lecture/disc time 5 | 17' |





Special Symposium - ESMO/ASCO Joint Symposium

Monday 15 September 2008, 10:45-12:15, Auditorium A1

| Monday 13 September | 2006, 10:45-12:15, Auditorium A1 |
|----------------------|---|
| Title symposium | ESMO/ASCO Joint Symposium: Assessing, reporting and managing the safety of oncology drugs |
| Co-Chairs | José Baselga, ES Richard L. Schilsky, US |
| Title presentation 1 | Introduction |
| Speaker 1 | José Baselga, ES |
| Lecture time 1 | 5' |
| Title presentation 2 | Detecting safety signals: The example of Herceptin cardiac toxicity |
| Speaker 2 | Thomas Suter, CH |
| Lecture/disc time 2 | 20' |
| Title presentation 3 | Monitoring toxicity on clinical trials: Under or over dosing? |
| Speaker 3 | Denis Lacombe, BE |
| Lecture/disc time 3 | 20' |
| Title presentation 4 | Global regulatory perspectives on drug safety |
| Speaker 4 | Renzo Canetta, US |
| Lecture/disc time 4 | 20' |
| Title presentation 5 | The role of pharmacogenetics in predicting and managing drug toxicity |
| Speaker 5 | Mark J. Ratain, US |
| Lecture/disc time 5 | 20' |
| Title presentation 6 | Conclusions |
| Speaker 6 | Richard L. Schilsky, US |
| Lecture/disc time 6 | 10' |





<u>Special Symposium</u> – Breast cancer

Monday, 15 September 2008, 10:45-12:15, Auditorium A3/4

| Monday, 15 September | er 2008, 10:45-12:15, Auditorium A3/4 |
|----------------------|---|
| Title symposium | Innovation in breast cancer care: selecting the best patient, exploring new treatment targets |
| Chair | Martine Piccart, BE |
| Co-Chair | Nadia Harbeck, DE |
| Title presentation 1 | Introduction |
| Speaker 1 | Nadia Harbeck, DE |
| Lecture time 1 | 5' |
| Title presentation 2 | Breast cancer stem cell as a potential treatment target |
| Speaker 2 | Piero Dalerba, US |
| Lecture/disc time 2 | 15' |
| Title presentation 3 | New treatment targets for triple negative breast cancer |
| Speaker 3 | Andrew Tutt, GB |
| Lecture/disc time 3 | 15' |
| Title presentation 4 | Modulation of resistance to anti-Her2 therapies |
| Speaker 4 | Fatima Cardoso, BE |
| Lecture/disc time 4 | 15' |
| Title presentation 5 | Evaluation of predictive markers on circulating tumor cells |
| Speaker 5 | Angelo Di Leo, IT |
| Lecture/disc time 5 | 15' |
| Title presentation 6 | ER/PgR and prediction of response to hormonotherapy. Can we do better? |
| Speaker 6 | Per Lønning, NO |
| Lecture/disc time 6 | 15' |
| Title presentation 7 | Conclusions |
| Speaker 7 | Martine Piccart, BE |
| Lecture time 7 | 10' |





Special Symposium - Sarcoma, melanoma and rare tumors

Monday, 15 September 2008, 11:00-12:30, Auditorium A6

| Worlday, 15 September | er 2008, 11:00-12:30, Auditorium A6 |
|-----------------------|--|
| Title symposium | Advances in soft tissue sarcoma, GIST and beyond |
| Chair | Patrick Schöffski, BE |
| Co-Chair | A. Paolo Dei Tos, IT |
| Title presentation 1 | Introduction |
| Speaker 1 | A. Paolo Dei Tos, IT |
| Lecture time 1 | 5' |
| Title presentation 2 | Molecular biology of sarcomas |
| Speaker 2 | Jean-Michel Coindre, FR |
| Lecture/disc time 2 | 20' |
| Title presentation 3 | GIST – the role of adjuvant therapy and mutational analysis in treatment decision-making |
| Speaker 3 | Peter Reichardt, DE |
| Lecture/disc time 3 | 20' |
| Title presentation 4 | Molecularly-targeted therapy of sarcoma |
| Speaker 4 | Jean-Yves Blay, FR |
| Lecture/disc time 4 | 20' |
| Title presentation 4 | Open issues in state-of-the-art of soft tissue sarcoma medical therapy |
| Speaker 4 | Paolo Casali, IT |
| Lecture/disc time 4 | 20' |
| Title presentation 6 | Conclusions |
| Speaker 6 | Patrick Schöffski, BE |
| Lecture/disc time 6 | 5' |





Special Symposium - Gastrointestinal tumors

Monday, 15 September 2008, 13:45-15:15, Auditorium A3/4

| Worlday, 15 September | er 2008, 13:45-15:15, Auditorium A3/4 | |
|-----------------------|--|--|
| Title symposium | Optimal integration of newer agents in the treatment of advanced colorectal cancer | |
| Chair | Udo Vanhoefer, DE | |
| Co-Chair | Jim Cassidy, GB | |
| Title presentation 1 | Introduction | |
| Speaker 1 | Jim Cassidy, GB | |
| Lecture time 1 | 10' | |
| Title presentation 2 | State-of-the-art strategies in first line treatment | |
| Speaker 2 | Alberto Sobrero, IT | |
| Lecture/disc time 2 | 15' | |
| Title presentation 3 | Standard and innovative approaches to salvage treatment | |
| Speaker 3 | Josep Tabernero, ES | |
| Lecture/disc time 3 | 15' | |
| Title presentation 4 | Optimal strategy to increase the resectability of liver/lung metastases | |
| Speaker 4 | Alfredo Falcone, IT | |
| Lecture/disc time 4 | 15' | |
| Title presentation 5 | Optimal treatment duration | |
| Speaker 5 | Hans Joachim Schmoll, DE | |
| Lecture/disc time 5 | 15' | |
| Title presentation 6 | The contribution of genomic and pharmacogenetic markers for treatment decision | |
| Speaker 6 | Patrick Johnston, GB | |
| Lecture/disc time 6 | 15' | |
| Title presentation 7 | Conclusions | |
| Speaker 7 | Udo Vanhoefer, DE | |
| Lecture time 7 | 5' | |





Special Symposium - Hematological malignancies and myeloma

Monday, 15 September 2008, 15:30-17:00, Victoria Hall

| Title symposium | What is the role of high dose therapy and allografting stemcell transplantation for hematological malignancies in the era of "-nibs" and "-mabs". |
|----------------------|---|
| Chair | Harry Schouten, NL |
| Co-Chair | Magnus Björkholm, SE |
| Title presentation 1 | Introduction |
| Speaker 1 | Harry Schouten, NL |
| Lecture time 1 | 5' |
| Title presentation 2 | Chronic myeloid leukemia |
| Speaker 2 | Jane Apperley, GB |
| Lecture/disc time 2 | 25' |
| Title presentation 3 | High grade lymphoma |
| Speaker 3 | Bertrand Coiffier, FR |
| Lecture/disc time 3 | 25' |
| Title presentation 4 | Low grade lymphoma |
| Speaker 4 | Armando Lopez Guillermo, ES |
| Lecture/disc time 4 | 25' |
| Title presentation 7 | Conclusions |
| Speaker 7 | Magnus Björkholm, SE |
| Lecture/disc time 7 | 10' |





<u>Special Symposium</u> - Developmental therapeutics

Monday, 15 September 2008, 15:30-17:00, Auditorium A3/4

| Monday, 15 September 2008, 15:30-17:00, Auditorium A3/4 | | |
|---|-----------------------------|--|
| Title symposium | Emerging new targeted drugs | |
| Chair | Chris Twelves, GB | |
| Co-Chair | Jean-Pierre Armand, FR | |
| Title presentation 1 | Introduction | |
| Speaker 1 | Chris Twelves, GB | |
| Lecture time 1 | 5' | |
| Title presentation 1 | IGF-1 receptor inhibitors | |
| Speaker 1 | Michael Pollak, CA | |
| Lecture/disc time 4 | 20' | |
| Title presentation 2 | PI3 kinase pathways | |
| Speaker 3 | Bart Vanhaesebroeck, GB | |
| Lecture/disc time 3 | 20' | |
| Title presentation 3 | PARP inhibitors | |
| Speaker 5 | Andrew Tutt, GB | |
| Lecture/disc time 5 | 20' | |
| Title presentation 4 | Met inhibitors | |
| Speaker 2 | Paolo Comoglio, IT | |
| Lecture/disc time 2 | 20' | |
| Title presentation 5 | Conclusions | |
| Speaker 5 | Jean-Pierre Armand, FR | |
| Lecture/disc time 5 | 5' | |





Special symposium

Tuesday, 16 September 2008, 09:15-10:45, Auditorium A6

| ruesday, re cepterns | Der 2006, 09.15-10.45, Auditorium A6 |
|----------------------|--------------------------------------|
| Title symposium | Emerging therapies for orphan tumors |
| Chair | Ahmad Awada, BE |
| Co-Chair | Patrick Schöffski, BE |
| Title presentation 1 | Introduction |
| Speaker 1 | Ahmad Awada, BE |
| Lecture time 1 | 5' |
| Title presentation 2 | Papillary renal cancer |
| Speaker 2 | Patricia Lorusso, US |
| Lecture/disc time 2 | 15' |
| Title presentation 3 | Thyroid cancer |
| Speaker 3 | Wieland Voigt, DE |
| Lecture/disc time 3 | 15' |
| Title presentation 4 | Hepatocellular carcinoma |
| Speaker 4 | Jordi Bruix, ES |
| Lecture/disc time 4 | 15' |
| Title presentation 5 | Neuroendocrine tumors |
| Speaker 5 | Eric van Cutsem, BE |
| Lecture/disc time 5 | 15' |
| Title presentation 6 | Conclusions |
| Speaker 6 | Patrick Schöffski, BE |
| Lecture/disc time 6 | 10' |





<u>Special Symposium</u> - ESMO/JSMO Joint Symposium

Tuesday, 16 September, 11.15-12.45, Auditorium A3/4

| rucsuay, 10 ocptomb | er, 11.15-12.45, Auditorium A5/4 | |
|----------------------|---|--|
| Title symposium | ESMO/JSMO Joint Symposium: Adenocarcinoma of the lung | |
| Co-Chair ESMO | Paris A. Kosmidis, GR | |
| Co-Chair JSMO | Nagahiro Saijo, JP | |
| Title presentation 1 | Introduction: Overview of state-of-the-art of lung cancer mutation resistance | |
| Speaker 1 | Nagahiro Saijo, JP | |
| Lecture time 1 | 5' | |
| Title presentation 2 | Mechanisms of resistance to EGRF agents | |
| Speaker 2 | Sam Murray, GR | |
| Lecture/disc time 2 | 20' | |
| Title presentation 3 | Signatures of metastatic behavior in lung adenocarcinoma | |
| Speaker 3 | Federico Cappuzzo, IT | |
| Lecture/disc time 3 | 20' | |
| Title presentation 4 | Personalized cancer therapies for non-EGFR receptor dependent tumors | |
| Speaker 4 | Rafael Rosell, ES | |
| Lecture/disc time 4 | 20' | |
| Title presentation 5 | Management of elderly patients with lung cancer | |
| Speaker 5 | Tomohide Tamura, JP | |
| Lecture/disc time 5 | 20' | |
| Title presentation 7 | Conclusions | |
| Speaker 7 | Paris A. Kosmidis, GR | |
| Lecture/disc time 7 | 5' | |





Special Symposium - Palliative and supportive

Tuesday, 16 September 2008, 11:15-12:45, Auditorium A6

| racoday, to coptomic | ici 2000, 11.13-12.43, Additionalii Ao |
|----------------------|---|
| Title symposium | Communication skills in advanced cancer care |
| Chair | Dirk Schrijvers, BE |
| Co-Chair | Florian Strasser, CH |
| Title presentation 1 | Introduction |
| Speaker 1 | Dirk Schrijvers, BE |
| Lecture time 1 | 5' |
| Title presentation 2 | Communication basic concepts applicable in advanced cancer care |
| Speaker 2 | Walter F. Baile, US |
| Lecture/disc time 2 | 20' |
| Title presentation 3 | Key communication skills |
| Speaker 3 | Lesley Fallowfield, GB |
| Lecture/disc time 3 | 20' |
| Title presentation 4 | Scientific evidence of effective communication interventions |
| Speaker 4 | Friedrich Stiefel, CH |
| Lecture/disc time 4 | 20' |
| Title presentation 5 | The use of communication skills: Lessons derived from microanalytical studies |
| Speaker 5 | Darius Razavi, BE |
| Lecture/disc time 5 | 20' |
| Title presentation 6 | Conclusions |
| Speaker 6 | Florian Strasser, CH |
| Lecture/disc time 6 | 5' |





<u>Controversy session</u> – Colorectal cancer

Sunday, 14 September 2008, 09:15-10:15, Auditorium A1

| Title controversy | Upfront sequential versus combination chemotherapy in advanced CRC |
|-------------------|--|
| Moderator | Eric Van Cutsem, BE |
| Lecture/disc time | 10' |
| Pro speaker | Cornelis Punt, NL |
| Lecture/disc time | 20' |
| Contra speaker | Aimery De Gramont, FR |
| Lecture/disc time | 20' |
| Moderator | Eric Van Cutsem, BE |
| Lecture/disc time | 10' |

Controversy session - Basic science

Sunday, 14 September 2008, 13:30-14:30, Auditorium A1

| Title controversy | Are unplanned analyses of molecular studies harmful? |
|---------------------|--|
| Moderator | Fabrice André, FR |
| Lecture/disc time | 10' |
| Pro speaker (Yes) | Stefan Michiels, FR |
| Lecture/disc time | 20' |
| Contra speaker (No) | Alessandra Gennari, IT |
| Lecture/disc time | 20' |
| Moderator | Fabrice André, FR |
| Lecture/disc time | 20' |

<u>Controversy session</u> – Palliative care

Sunday, 14 September 2008, 16:30-17:30, Auditorium A1

| Title controversy | Should all cancer patients receive prophylactically antithrombotic therapy? |
|-------------------|---|
| Moderator | Roberto Labianca, IT |
| Lecture/disc time | 10' |
| Pro speaker | Hans-Martin Otten, NL |
| Lecture/disc time | 20' |
| Contra speaker | Ajay Kakkar, GB |
| Lecture/disc time | 20' |
| Moderator | Roberto Labianca, IT |
| Lecture/disc time | 10' |





<u>Controversy session</u> – Breast cancer

Monday, 15 September 2008, 09:15-10:15, Auditorium A1

| Title controversy | Trastuzumab in the adjuvant setting: Is combination with chemotherapy better than sequential treatment? |
|-------------------|---|
| Moderator | Michael Untch, DE |
| Lecture/disc time | 10' |
| Pro speaker | John Crown, IE |
| Lecture/disc time | 20' |
| Contra speaker | Ian Smith, GB |
| Lecture/disc time | 20' |
| Moderator | Michael Untch, DE |
| Lecture/disc time | 10' |

Controversy session - Sarcoma

Tuesday, 16 September 2008, 09:15-10:15, Auditorium A1

| Title controversy | Hyperthermia has been shown to improve local control of soft tissue sarcomas: Should this now be standard therapy? |
|-------------------|--|
| Moderator | Alessandro Gronchi, IT |
| Lecture/disc time | 10' |
| Pro speaker | Rolf Issels, DE |
| Lecture/disc time | 20' |
| Contra speaker | Martin Robinson, GB |
| Lecture/disc time | 20' |
| Moderator | Alessandro Gronchi, IT |
| Lecture/disc time | 10' |





Patient cases - open sessions

Saturday, 13 September 2008, 08:00-09:00, Auditorium K1

| Topic | Ovarian and endometrial cancer: Challenge the experts and your peers with difficult cases! |
|--|--|
| Moderator (plus 'panel' of other speakers in this topic) | Gunnar Kristensen, NO plus ovarian /endometrial speakers |

Sunday, 14 September 2008, 08:00-09:00, Auditorium K1

| Topic | Treatment of localized prostate cancer: Challenge the experts and your peers with difficult cases! |
|--|--|
| Moderator (plus 'panel' of other speakers in this topic) | Hein Van Poppel, BE plus prostate speakers |

Monday, 15 September 2008, 08:00-09:00, Auditorium K1

| Topic | Locoregional relapses from BC: Challenge the experts and your peers with difficult cases! |
|--|---|
| Moderator (plus 'panel' of other speakers in this topic) | Jonas Bergh, SE plus breast speakers |

Tuesday, 16 September 2008, 08:00-09:00, Auditorium K1

| Topic | Treatment of extensive stage SCLC: Challenge the experts and your peers with difficult cases! |
|--|---|
| Moderator (plus 'panel' of other speakers in this topic) | Pieter Postmus, NL plus lung speakers |





Patient cases - Organized sessions

Saturday, 13 September 2008, 08:00-09:00, Auditorium A6

| outurus, ro objetember 2000, torior outer, riamiterium rio | |
|--|--|
| Topic | Second line treatment in NSCLC |
| Co-Chairs (and speakers) | Panos Fidias, US and Nick Thatcher, GB |

Sunday, 14 September 2008, 08:00-09:00, Auditorium A6

| Topic | Breast cancer during pregnancy: What to do |
|--------------------------|--|
| Co-Chairs (and speakers) | Fedro Peccatori, IT and Alistair Ring, GB |

Monday, 15 September 2008, 08:00-09:00, Auditorium A6

| Topic | Difficult cases in rectal cancer |
|--------------------------|---|
| Co-Chairs (and speakers) | Bengt Glimelius, SE and Cornelis Van de Velde, NL |

Tuesday, 16 September 2008, 08:00-09:00, Auditorium A6

| Topic | Difficult cases in palliative care |
|--------------------------|--|
| Co-Chairs (and speakers) | Dirk Schrijvers, BE and Florian Strasser, CH |





ESMO 2008 Educational sessions

| 1. | Lung cancer: New opportunities | Chair: Giuseppe Giaccone, US |
|-------|---|---|
| | | Co-chair: Giannicola D'Addario, CH |
| | creening and early diagnosis | Pieter Postmus, NL |
| | nanging algorithm in staging | Walter Weder, CH |
| - Ne | ew opportunities in systemic therapy | Giuseppe Giaccone, US |
| 2. | Which tools can I use in daily clinical practice to improve tailoring of treatment for breast cancer? | Chair: Angelo Di Leo, IT Co: chair: Nagi El Saghir, LB |
| - Th | e 2007 St. Gallen guidelines and/or adjuvant on-line | Tanja Cufer, SL |
| - Tre | eatment tailoring based on molecular characterization (early and adv) | Christos Sotiriou, BE |
| - Tre | eatment decision-making in advanced disease | Ian Smith, GB |
| 3. | Multimodality treatment in locoregional gynecological cancer: State of the art | Chair: Andres Poveda, ES Co-chair: Vladimir Todorovic, ME |
| - Ov | rarian cancer: Front-line standard treatment in 2008 | Paul Vasey, AU |
| | dometrial cancer: Adjuvant treatment of endometrial cancer: otherapy, chemotherapy or both? | Nick Reed, GB |
| | rvical cancer: treatment update | Andres Poveda, ES |
| 4. | Advanced prostate cancer | Chair: Ian Tannock, CA Co-chair: Vahur Valvere, EE |
| -The | changing face of hormonal therapy | Ian Tannock, CA |
| | abetes and cardiovascular disease in prostate cancer survivors | Matthew Smith, US |
| -Sys | stemic chemotherapy and new experimental approaches | Cora Sternberg, IT |
| 5. | Challenges in treating older cancer patients | Chair: Demetris Papamichael, CY |
| | | Co-chair: Riccardo Audisio, GB |
| | east cancer | Hans Wildiers, BE |
| | lon cancer | Demetris Papamichael, CY |
| - Lu | ng cancer | Cesare Gridelli, IT |
| 6. | New developments in myeloma | Chair: Jean-Luc Harousseau, FR Co-chair: Nino Sharikadze, GE |
| | ognostic factors in the management of myeloma | Joan Blade, ES |
| | e role of novel drugs in myeloma | Meletios Dimopoulos, GR |
| -The | e status of transplantation in myeloma | Jean-Luc Harousseau, FR |
| 7. | Important issues in supportive care | Chair: Josep Tabernero, ES Co-chair: B. Koczwara, AU |
| - Er | ythropoietic stimulating agents. Where do we stand? | Mario Dicato, LU |
| - Mu | cositis in the treatment of hematologic malignancies | Pasquale Niscola, IT |
| - Ha | andling side effects of targeted agents | Josep Tabernero, ES |
| 8. | State-of-the-art approach in selective curable tumors | Chair: Ian Judson, GB Co-chair: Jean-Yves Blay, FR |
| | ne-sarcoma | Stefan Bielack, DE |
| | erm cell tumors | Gordon J. Rustin, GB |
| - So | ft tissue sarcoma | Ian Judson, GB |
| | | |





| cancer care - What new technology and what for? - Is there an impact on the treatment of breast cancer? - Is there an impact on the treatment of colorectal cancer? - Is there an impact on the treatment of colorectal cancer? - Is there an impact on the treatment of colorectal cancer? - Viruses in head and neck cancers: prevention and therapy - Strengths and weaknesses in multidisciplinary treatment of locally advanced head and neck cancer - Recurrent and metastatic head and neck cancer: new options - Wanagement of glioma - Management of glioma - Roger Stupp, CH - Roger Stupp, CH | , |
|---|----------|
| - Is there an impact on the treatment of breast cancer? - Is there an impact on the treatment of colorectal cancer? 10. Optimizing approaches to head and neck cancer - Viruses in head and neck cancers: prevention and therapy - Strengths and weaknesses in multidisciplinary treatment of locally advanced head and neck cancer - Recurrent and metastatic head and neck cancer: new options 11. Management of glioma - Imaging of glioma - Luca Gianni, IT David Kerr, GB Chair: Lisa Licitra, IT Amanda Psyrri, US Jordi Giralt, ES Lisa Licitra, IT Chair: Roger Stupp, CH Co-chair: Bojana Pajk, SI Karl Herholz, GB | ; |
| - Is there an impact on the treatment of colorectal cancer? 10. Optimizing approaches to head and neck cancer - Viruses in head and neck cancers: prevention and therapy - Strengths and weaknesses in multidisciplinary treatment of locally advanced head and neck cancer - Recurrent and metastatic head and neck cancer: new options 11. Management of glioma Chair: Roger Stupp, CH Co-chair: Bojana Pajk, SI - Imaging of glioma Karl Herholz, GB |) |
| 10. Optimizing approaches to head and neck cancer - Viruses in head and neck cancers: prevention and therapy - Strengths and weaknesses in multidisciplinary treatment of locally advanced head and neck cancer - Recurrent and metastatic head and neck cancer: new options - Recurrent and metastatic head and neck cancer: new options - Management of glioma - Chair: Lisa Licitra, IT - Jordi Giralt, ES - Lisa Licitra, IT - Chair: Roger Stupp, CH - Co-chair: Bojana Pajk, SI - Imaging of glioma - Karl Herholz, GB | |
| - Viruses in head and neck cancers: prevention and therapy - Strengths and weaknesses in multidisciplinary treatment of locally advanced head and neck cancer - Recurrent and metastatic head and neck cancer: new options 11. Management of glioma Co-chair: Jose Trigo-Perez, ES Amanda Psyrri, US Jordi Giralt, ES Lisa Licitra, IT Chair: Roger Stupp, CH Co-chair: Bojana Pajk, SI - Imaging of glioma Karl Herholz, GB | ; |
| - Strengths and weaknesses in multidisciplinary treatment of locally advanced head and neck cancer - Recurrent and metastatic head and neck cancer: new options 11. Management of glioma Chair: Roger Stupp, CH Co-chair: Bojana Pajk, SI - Imaging of glioma Karl Herholz, GB | |
| advanced head and neck cancer - Recurrent and metastatic head and neck cancer: new options Lisa Licitra, IT 11. Management of glioma Chair: Roger Stupp, CH Co-chair: Bojana Pajk, SI - Imaging of glioma Karl Herholz, GB | |
| 11. Management of glioma Chair: Roger Stupp, CH Co-chair: Bojana Pajk, SI - Imaging of glioma Karl Herholz, GB | |
| Co-chair: Bojana Pajk, SI - Imaging of glioma Karl Herholz, GB | |
| 0 0 | |
| Management of gliome | |
| | |
| - Role of radiotherapy in low grade glioma Brigitta Baumert, NL | |
| 12.Clinical cancer control and preventionChair: Hans-Joerg Senn, CHCo-chair: Bo Nordenskjöld SE | |
| - Inflammation and cancer prevention Andrea Decensi, IT | |
| - Eliminating tobacco-induced cancers: A worldwide challenge Daniel Bettcher, CH | |
| - Chemoprevention of breast and prostate cancer: Where do we stand? Hans-Joerg Senn, CH | |
| 13.Recent progress in immunotherapyChair: Heinz Zwierzina, AT Co-chair: Vasile Musteata, MD | |
| - Overcoming immunosuppressor mechanisms Hakan Mellstedt, SE | |
| - Anti cancer vaccines: Emerging clinical data Angus Dalgleish, GB | |
| - Combining immunotherapy with classical anti-cancer therapy Heinz Zwierzina, AT | |
| 14. Progress in the multidisciplinary treatment of GI cancers, impact on clinical practice Chair: David Cunningham, GB Co-chair: Gunta Purkalne, LV | |
| - Perioperative management of gastroesophageal cancer David Cunningham, GB | |
| - Perioperative management of rectal cancer Andrés Cervantes ES | |
| - Perioperative management of pancreatic cancer Volker Heinemann, DE | |

Challenge Your Expert sessions

| How and why to perform a geriatric assessment in clinical practice | Catherine Terret, FR |
|--|-----------------------|
| The treatment of advanced pancreatic cancer: current evidence and future | Malcolm Moore, CA |
| challenges | |
| Novel agents in the era of targeted therapy – What have we learned and how | José Baselga, ES |
| has our practice changed? | |
| Management of anorexia and weight loss | Jane Hopkinson, GB |
| Novel radiotherapy tools | Suresh Senan, NL |
| Thymic malignancies | Egbert Smit, NL |
| Chronic lymphocytic leukemia | Emilio Montserrat, ES |
| Balancing costs and benefits in cancer therapy and prevention | Thomas Szucs, CH |





YO Masterclass

Friday, 12 September 2008, 14:00-17:00, K22/K23 13:00-14:00 Masterclass lunch

| 13.00-14.00 Masterciass functi | |
|--------------------------------|---|
| Title session | Understanding and preparing a paper on translational research |
| Co-Chairs | Serena Di Cosimo, ES and Jean-Charles Soria, FR |
| Title presentation 1 | How to analyze a translational research paper |
| Speaker 1 | Jean-Charles Soria, FR |
| Lecture/discussion time 1 | 30' |
| Title presentation 2 | How to write a translational research paper |
| Speaker 2 | José Baselga, ES |
| Lecture/discussion time 2 | 30min |
| Coffee break | 20' |
| Title presentation 3 | How to judge a translational research paper |
| Speaker 3 | Christian Dittrich, AT |
| Lecture/discussion time 3 | 30' |
| Title presentation 4 | YOs and research: Results from a European survey |
| Speaker 4 | Svetlana Jezdic, CH |
| Lecture/discussion time 4 | 20' |
| Break | 10' |
| Title presentation 5 | How ESMO can help YO interests in anti-cancer research |
| Speaker 5 | Aage Schultz, CH |
| Lecture/discussion time | 20' |
| Title presentation 6 | Wrap-up discussion |
| Speaker 6 | Serena Di Cosimo, ES |
| Lecture/discussion time | 20' |





YO Breakfasts

Saturday 13 September 2008, 08:00-08:45

| tanamata) to copiumitat =cos, coros coros | |
|---|-----------------------|
| Title session 1 | Cancer during youth |
| Speaker 1 | Michele Ghielmini, CH |
| Lecture/discussion time 1 | 45' |

Sunday 14 September 2008, 08:00-08:45

| Type session 2 | Fertility, pregnancy and cancer |
|---------------------------|---------------------------------|
| Speaker 2 | Nicholas Pavlidis, GR |
| Lecture/discussion time 2 | 45' |

Monday 15 September 2008, 08:00-08:45

| Type session 3 | The ESMO young oncologist grant program: Presentation and feedback |
|-----------------|--|
| Speaker 3 | Serena Di Cosimo, ES |
| Lecture time 3 | 20' |
| Speaker 4 | Aleksandar Celebic, SRB |
| Lecture time 4 | 20' |
| Discussion time | 5 mins |





YO Forum

Monday 15 September 2008, 09:15-10:45

| Worlday 13 September 20 | 700, 00.10 10.40 |
|-------------------------|--|
| Topic | Late drug development |
| Chair | Marina Garassino, IT |
| Co-Chair | Serena Di Cosimo, ES |
| Title presentation 1 | Introduction |
| Speaker 1 | Marina Garassino, IT |
| Lecture time 1 | 5' |
| Title presentation 1 | How to recognize a promising drug: The role of clinical and biological endpoints |
| Speaker 1 | Michele Milella, IT |
| Lecture/disc time | 25' |
| Title presentation 2 | Scientific research organizations and cooperative groups |
| Speaker 2 | Carolyn Straehle, BE |
| Lecture/disc time 2 | 25' |
| Title presentation 3 | The role of regulatory bodies in the drug approval process |
| Speaker 3 | Francesco Pignatti / EMEA, GB |
| Lecture/disc time 3 | 25' |
| Title presentation 4 | Getting an approved drug to be used on an extended basis |
| Speaker 4 | Filippo de Braud, IT |
| Lecture/disc time 4 | 25' |
| Title presentation 5 | Conclusions |
| Speaker 5 | Serena Di Cosimo, ES |
| Lecture/disc time 5 | 5' |